
La Grange Restaurant Week offers post-Valentine's Day business boost
La Grange Restaurant Week, which kicks off Feb. 27, is a great way to offer some good exposure to area eateries at a time that can typically be slow for the businesses, participants said.
Encompassing two weekends, the event's name is something of a misnomer.
'It's 10 days long, Thursday to Sunday, so it's a good week and a half for us,' said Joe Dellacroce, owner of GP Italiano, a Restaurant Week regular since opening in 2021.
'Restaurant Week is awesome,' he said. 'It brings a lot of people out to this area during these cold winter months. During Restaurant Week, it means that we will be able to fill up the restaurant and give us a good push for the winter.
During the 14th edition of one of the Western Suburbs signature culinary events, from Feb. 27 through March 9, 22 La Grange dining establishments will offer special menus reflecting the village's culinary heritage.
'I like to say that Restaurant Week is a great excuse to get a meal and a dessert,' said Dan Mulka, executive director of the La Grange Business Association, which presents the annual promotion with the village of La Grange. 'You're saving money with some of the meals, and you get to try things you may not usually try.'
GP Italiano, 1 S. LaGrange Rd., will offer special prices on various menu items to make a four-course meal. Specialties at Milk Money Brewing, 75 S. La Grange Road, will include blackened mahi mahi, Chicago-style pizza and hickory-smoked pork rib sliders. Woow Japanese Restaurant and Sushi, 35 S. La Grange Rd., will feature a three-course sushi dinner roll menu.
Other participating restaurants include Marco's Kitchen, mána, Aodake Ramen, Barrel House Social, Blackberry Market, fourteensixteen, The Elm, Hangry Joe's, Kama Indian Bistro, Milkstop Cafe, Nonna's Goodlife Pizza, Prasino, Q BBQ, Santiago's, Shang Noodle, Steak + Vine, Sushi Ukai, Uppers Land and Wonderful Matcha. The complete list of restaurants and some specials are listed at lgba.com.
Mulka said that he and LGBA representative Alissa Wade already sampled the fare at Hangry Joe's Hot Chicken and Wings, 1 N. La Grange Road, which opened late last year.
He even tried the hottest sauce available, that Hangry Joe's makes customers sign a waiver before serving it.
'I took a bite and it was about two minutes before I broke into a complete sweat, and I only had a bite,' he said laughing.
Dellacroce said he appreciates the LGBA's efforts to boost the downtown restaurant district, particularly through social media promotions.
'The La Grange Business Association does a really good job of exposing businesses throughout that time,' he said. 'It really brings a lot of people that maybe would not come to the La Grange and it brings them out here. If they're not coming to GP, they're next door at Kama, and see that there's a wood-fired pizza place and a place that's selling pasta next door. They'll remember that and come out in the next couple weeks and see us.'
Stephanie Posey, president of the LGBA and proprietor of the Posey Law Group, said La Grange Restaurant Week provides benefits above and beyond great food, though it does showcase 'the incredibly diverse flavors that make our town special.'
'There is nothing like sharing a meal with friends and family,' she said. 'Great local food has the power to bring people together.'
Although sponsorship of Restaurant Week is done by LGBA and the Village, other community members also help to promote the event.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
an hour ago
- Associated Press
Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)
HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, 'Ascletis') announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be presented at the 85th Scientific Sessions of American Diabetes Association (ADA) in Chicago, U.S. Details of the Poster Presentations Poster Number: 750-P Abstract Title: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) Poster Number: 847-P Abstract Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) About ASC30 ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044. About ASC47 ASC47 is an adipose-targeted, ultra-long-acting subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue. Topline data from its Phase Ib single subcutaneous injection studies in Australia in participants with elevated low-density lipoprotein cholesterol (LDL-C) ( NCT06427590 ) have been released. The Phase I clinical trial of ASC47 in combination with semaglutide for the treatment of obesity ( NCT06972992 ) is ongoing in the U.S., and the first participants were dosed in May 2025. About the American Diabetes Association (ADA) Established in 1940, the American Diabetes Association (ADA) is dedicated to preventing and curing diabetes and to improving the lives of all people affected by diabetes. It has grown into one of the foremost nonprofit organizations in diabetes advocacy around the world. Its annual Scientific Sessions set the agenda for clinical practice and research innovation. The 85th Scientific Sessions of ADA will be held in Chicago, U.S. from June 20 to 23, 2025. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange ( covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline. For more information, please visit Contact: Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) [email protected] Ascletis Pharma Inc. PR and IR teams +86-181-0650-9129 (China) [email protected] [email protected] View original content: SOURCE Ascletis Pharma Inc.
Yahoo
2 hours ago
- Yahoo
Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)
HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be presented at the 85th Scientific Sessions of American Diabetes Association (ADA) in Chicago, U.S. Details of the Poster Presentations Poster Number: 750-P Abstract Title: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) Poster Number: 847-P Abstract Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) About ASC30 ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044. About ASC47 ASC47 is an adipose-targeted, ultra-long-acting subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue. Topline data from its Phase Ib single subcutaneous injection studies in Australia in participants with elevated low-density lipoprotein cholesterol (LDL-C) (NCT06427590) have been released. The Phase I clinical trial of ASC47 in combination with semaglutide for the treatment of obesity (NCT06972992) is ongoing in the U.S., and the first participants were dosed in May 2025. About the American Diabetes Association (ADA) Established in 1940, the American Diabetes Association (ADA) is dedicated to preventing and curing diabetes and to improving the lives of all people affected by diabetes. It has grown into one of the foremost nonprofit organizations in diabetes advocacy around the world. Its annual Scientific Sessions set the agenda for clinical practice and research innovation. The 85th Scientific Sessions of ADA will be held in Chicago, U.S. from June 20 to 23, 2025. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange ( covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline. For more information, please visit Contact: Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) Ascletis Pharma Inc. PR and IR teams +86-181-0650-9129 (China) pr@ ir@ View original content: SOURCE Ascletis Pharma Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
I'm a Gen Zer who landed a 6-figure job at Morgan Stanley before graduation. Here's what the process was like — and why you should refresh a surprisingly important part of your résumé.
Sara Thomas, a University of Chicago student, secured a role at Morgan Stanley before graduation. She said networking, campus finance clubs, and an often overlooked resumé section helped her land the role. Gen Z continues to be attracted to Wall Street careers, despite the long hours and high demands. This as-told-to essay is based on a conversation with Sara Thomas, 22, a 2025 graduate from the University of Chicago and incoming investment banking analyst at Morgan Stanley. Business Insider's recent "Path to Wall Street" series highlighted how finance careers continue to attract young talent, despite the industry's long hours and demanding entry-level roles. Entry-level bankers typically earn about $110,000 a year, not including bonuses. This interview has been edited for length and clarity. I had barely decided on banking as a career choice when I had to start preparing for interviews. My experience was similar to most stories I've heard about the banking world: the recruiting process starts early. Before submitting my internship applications, I spoke to about five people at each major bank — mostly recent UChicago grads and people the university's career advancement program connected me with — so they would recognize my name when they saw my résumé. Cold LinkedIn messaging didn't work very well for me. Those introductions are often necessary to get an interview. At most banks, I interviewed for multiple rounds, including calls focused on my personality and technical skills and a two-hour "super day." The whole process lasted about two weeks. Then, by the spring of my sophomore year, I was done. I landed an internship at Morgan Stanley, and I knew my full-time job would be set as long as I got a return offer. My prior internships had been at Bain Capital and the Chicago-based firm Ariel Investments. The only other career trajectory I considered in college was academia. I studied economics and considered getting involved with economics research, but I realized it wasn't for me. I just work better in a faster-paced finance environment. In my free time at school, I tried to focus on clubs and internships that would keep me close to startups and entrepreneurship, so I joined a venture capital fund on campus. I was also involved in a campus group for women and minorities interested in finance and investing. Those opportunities really helped me build my industry chops. I would tell any college student hoping to land a Wall Street or Silicon Valley job: be decisive. Even if investment banking or consulting isn't your lifelong passion, plan to commit to a career path sooner rather than later, so that you can give yourself the most amount of time to prepare, network, and do really well in the interviews. And, for the application process, students need to be careful with what they put on their résumé — recruiters pay a lot of attention to the "skills and interests" section at the bottom. Don't say that you're a mountain climber if you have never climbed a mountain, because people will ask you about your hobbies, and you need to be able to genuinely talk about them. Of course, your credentials matter, but I've found that recruiters are most interested in meeting well-rounded people. Job applications and postgrad life make me anxious sometimes. I've leaned on my friends a lot: Some aren't going into finance, others have gone through recruiting alongside me. I'm also grateful for my family — my Morgan Stanley role will be in San Francisco, and it will be the first time I've moved far from home, since I grew up in Chicago. Exercise has always been a coping strategy for me, too. I'm trying to build healthy habits and make sure I don't isolate myself. Those are the main ways I'm dealing with stress. Long, long term, my biggest goal is to be able to work for myself in some way. That could mean working at a big company that gives me a lot of autonomy to make decisions or starting my own company, if I am brave enough to do that. For now, I'm excited to keep building my career and learning from my coworkers. Having engaging conversations with people you've never met can be the most challenging part of the finance industry, but it's also the most rewarding. Do you have a story to share? Contact this reporter at allisonkelly@ or via Signal at alliekelly.10; here's our guide to sharing information securely. Read the original article on Business Insider